Savara (SVRA) Competitors

Savara (NASDAQ:SVRA) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings, risk and community ranking.

Is SVRA or FOLD more profitable?

Savara has a net margin of 0.00% compared to Amicus Therapeutics' net margin of -10.62%. Amicus Therapeutics' return on equity of 12.44% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-58.89%	-46.44%
Amicus Therapeutics	-10.62%	12.44%	2.60%

Do analysts recommend SVRA or FOLD?

Savara currently has a consensus price target of $8.83, indicating a potential upside of 159.80%. Amicus Therapeutics has a consensus price target of $16.22, indicating a potential upside of 143.21%. Given Savara's stronger consensus rating and higher possible upside, analysts clearly believe Savara is more favorable than Amicus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Amicus Therapeutics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70

Does the media refer more to SVRA or FOLD?

In the previous week, Amicus Therapeutics had 11 more articles in the media than Savara. MarketBeat recorded 16 mentions for Amicus Therapeutics and 5 mentions for Savara. Savara's average media sentiment score of 0.86 beat Amicus Therapeutics' score of 0.59 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amicus Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, SVRA or FOLD?

Savara has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in SVRA or FOLD?

87.9% of Savara shares are held by institutional investors. 5.1% of Savara shares are held by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the MarketBeat Community believe in SVRA or FOLD?

Amicus Therapeutics received 232 more outperform votes than Savara when rated by MarketBeat users. Likewise, 72.91% of users gave Amicus Therapeutics an outperform vote while only 66.89% of users gave Savara an outperform vote.

Company	Underperform	Outperform
Savara	Outperform Votes 301 66.89%	Underperform Votes 149 33.11%
Amicus Therapeutics	Outperform Votes 533 72.91%	Underperform Votes 198 27.09%

Which has preferable earnings & valuation, SVRA or FOLD?

Savara has higher earnings, but lower revenue than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$54.70M	-$0.47	-7.23
Amicus Therapeutics	$528.30M	3.89	-$151.58M	-$0.18	-37.06

Summary

Amicus Therapeutics beats Savara on 9 of the 17 factors compared between the two stocks.